Novo Nordisk shared recent findings from two phase 3a trials of oral Semaglutide at the American Diabetes Association annual meeting. The drug reduced A1C levels and supported weight loss in type 2 diabetes patients compared to controls. Results from PIONEER 2 and PIONEER 4 trials showed…
Novo Nordisk disclosed new information from two phase 3a clinical trials on its oral Semaglutide during the annual meeting of the American Diabetes Association. In patients diagnosed with type 2 diabetes mellitus, the treatment lowered blood sugar levels more effectively than the comparator medication. It also assisted with weight reduction.
Semaglutide functions as a human glucagon-like peptide-1 analog. Past clinical trials have demonstrated positive outcomes for this compound.
Semaglutide mimics natural human glucagon-like peptide-1, known as GLP-1. This allows it to boost insulin secretion based on glucose levels, block glucagon release, and curb hunger along with food consumption.
When compared to Liraglutide, Semaglutide features a lengthier fatty acid chain and greater hydrophobicity. However, modifications with short chain PEG improve its water solubility substantially. These changes enable tight binding to albumin, shield against DPP-4 enzyme breakdown, limit kidney clearance, extend half-life, and support prolonged presence in the body.
This agent activates glucagon-like peptide-1 receptors. It raises insulin output, the hormone responsible for decreasing blood glucose. Evidence suggests it fosters beta cell expansion in the pancreas, the site of insulin manufacture.
Semaglutide counters glucagon, which elevates blood sugar. It diminishes appetite to cut food intake and delays gastric emptying. These actions contribute to fat mass reduction.
The presented data came from PIONEER 2 and PIONEER 4 studies. In PIONEER 2, patients received oral Semaglutide at 14 mg or empagliflozin at 25 mg. At 26 weeks, A1C reductions stood at 1.3% for Semaglutide versus 0.9% for empagliflozin, with p < 0.0001, meeting the primary endpoint.
For the secondary endpoint at 52 weeks, A1C dropped notably with oral Semaglutide. Weight loss showed no meaningful difference between groups.
In PIONEER 4, oral Semaglutide 14 mg matched Victoza in A1C reduction at 26 weeks, proving non-inferiority, and outperformed placebo significantly. At 52 weeks, it surpassed both Victoza and placebo on A1C control.
These results highlight oral Semaglutide's performance in managing type 2 diabetes through glycemic control and weight management in the specified trials.
---
Looking for high-purity research peptides? Browse our catalog for HPLC-verified compounds.
| Compound | Purity | Size | Price |
|---|---|---|---|
| Semaglutide 10mg /product/semaglutide-10mg | ≥98% | 10mg | $49.00 |
Browse Full Catalog → /catalog
Peptides referenced: Semaglutide, Liraglutide, Glucagon, GLP-1.
Related reading: FDA Approves Foundayo for Weight Loss in Orforglipron News, FDA Eyes Lifting Restrictions on Cosmetic Peptides, Is Tirzepatide Better Than Semaglutide for Weight Loss? Comparison, FDA Shake-Up and Growing Frustration with Prior Auth Reform.